AI System may Accelerate Search for Cancer Discoveries

Searching through the mountains of published cancer research could be made easier for scientists, thanks to a new AI system. The system, called LION LBD and developed by computer scientists and cancer researchers at the University of Cambridge, has been designed to assist scientists in the search for cancer-related discoveries. It is the first literature-based discovery system aimed at supporting cancer research. The results are reported in the journal Bioinformatics.

Global cancer research attracts massive amounts of funding worldwide, and the scientific literature is now so huge that researchers are struggling to keep up with it: critical hypothesis-generating evidence is now often discovered long after it was published.

Cancer is a complex class of diseases that are not completely understood and are the second-leading cause of death worldwide. Cancer development involves changes in numerous chemical and biochemical molecules, reactions and pathways, and cancer research is being conducted across a wide variety of scientific fields, which have variability in the way that they describe similar concepts.

"As a cancer researcher, even if you knew what you were looking for, there are literally thousands of papers appearing every day," said Professor Anna Korhonen, Co-Director of Cambridge's Language Technology Lab who led the development of LION LBD in collaboration with Dr Masashi Narita at Cancer Research UK Cambridge Institute and Professor Ulla Stenius at Karolinska Institutet in Sweden. "LION LBD uses AI to help scientists keep up-to-date with published discoveries in their field, but could also help them make new discoveries by combining what is already known in the literature by making connections between sources that may appear to be unrelated."

The 'LBD' in LION LBD stands for Literature-Based Discovery, a concept developed in the 1980s which seeks to make new discoveries by combing pieces of information from disconnected sources. The key idea behind the original version of LBD is that concepts that are never explicitly linked in the literature may be indirectly linked through intermediate concepts.

The design of the LION LBD system allows real-time search to discover indirect associations between entities in a database of tens of millions of publications while preserving the ability of users to explore each mention in its original context.

"For example, you may know that a cancer drug affects the behaviour of a certain pathway, but with LION LBD, you may find that a drug developed for a totally different disease affects the same pathway," said Korhonen.

LION LBD is the first system developed specifically for the needs of cancer research. It has a particular focus on the molecular biology of cancer and uses state-of-the-art machine learning and natural language processing techniques, in order to detect references to the hallmarks of cancer in the text. Evaluations of the system have demonstrated its ability to identify undiscovered links and to rank relevant concepts highly among potential connections.

The system is built using open data, open source and open standards, and is available as an interactive web-based interface or a programmable API.

The researchers are currently working on extending the scope of LION-LBD to include further concepts and relations. They are also working closely with cancer researchers to help and improve the technology for end users.

The system was developed in collaboration with University of Cambridge Language Technology Lab, Cancer Research UK Cambridge Institute, and Karolinska Institutet in Sweden, and was funded by the Medical Research Council.

Sampo Pyysalo, Simon Baker, Imran Ali, Stefan Haselwimmer, Tejas Shah, Andrew Young, Yufan Guo, Johan Högberg, Ulla Stenius, Masashi Narita, Anna Korhonen.
LION LBD: a literature-based discovery system for cancer biology.
Bioinformatics, doi: 10.1093/bioinformatics/bty845.

Most Popular Now

A New Machine Learning Model can Classif…

Machine learning has improved dramatically in recent years and shown great promise in the field of medical image analysis. A team of research specialists at Dartmouth's Norris Cotton Cancer Center...

Could Blockchain Ensure Integrity of Cli…

UC San Francisco researchers have created a proof-of-concept method for ensuring the integrity of clinical trials data with blockchain. The system creates an immutable audit trail that makes it easy...

3D Child Welfare: How Data, Design and D…

Opinion Article by Rainer Binder, Managing Director, Global Employment and Social Services, Accenture Child welfare remains a pressing challenge for governments around the world, and the statistics are heart-breaking. In the...

Bringing more Human Intelligence to AI, …

The advent of data science, wireless connectivity and sensors, artificial intelligence (AI), and the Internet of Things (IoT) has raised the prospects for digital automation, smart hospital design and the...

Scotland's Digital Health Leaders Recogn…

Scotland's digital health champions have been recognised for their achievements at the Holyrood Connect Digital Health and Care Awards 2019. William Edwards, director of eHealth at NHS Greater Glasgow and...

DMEA 2019: International Exchange on Dig…

9 - 11 April 2019, Berlin, Germany. DMEA (formerly conhIT) is the industry's main event for digital healthcare. In that context, an international exchange of experiences and networking beyond national borders...

Philips to Expand its Radiology Informat…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it has signed an agreement to acquire the Healthcare Information Systems business of Carestream Health...

Three Winners of 2019 Sandoz Healthcare …

Sandoz, a Novartis division, announced the winners of the 2019 Sandoz Healthcare Access Challenge (HACk). Sandoz HACk invites entrepreneurs and innovators in the field of digital technology to submit ideas...

UK Sales of Xanax and other Prescription…

Sales of prescription psychiatric drugs such as Xanax and diazepam via darknet online drug markets have increased in the UK at an alarming rate, according to new research by the...

Accenture Wins GLOMO Award for Virtual R…

The Accenture (NYSE: ACN) Virtual Experience Solutions (AVEnueS) has won "Best Mobile VR or AR" at the GSMA GLOMO Awards 2019. The award was presented at MWC19 Barcelona.

Study Finds Robots can Detect Breast Can…

Breast cancer is the most common cancer in women, and despite important improvements in therapy, it is still a major cause for cancer-related mortality, accounting for approximately 500,000 annual deaths...